A major challenge for the management of colorectal liver metastasis (CRLM) is the multidisciplinary approach including surgery. Resection is the most important treatment strategy to prolong the survival of patients with colorectal cancer (CRC). Even when resection is not possible as a primary treatment, it may still be carried out for curative intent after effective chemotherapy. Therefore, resection should always be considered when conducting chemotherapy for CRLM. Neoadjuvant anti-epidermal growth factor receptor (EGFR) antibody has shown a high response rate for RAS wild CRC. However, whether anti-EGFR antibody is superior to antivascular endothelial growth factor antibody for all types of CRLM is yet to be determined. Recently, several randomized control trials of first-line therapy for advanced CRC have been conducted, and some of them are ongoing. The optimal chemotherapy regimen and tumor biology indicated for neoadjuvant chemotherapy as well as conversion surgery are expected to be determined in the near future. Cancer Research, more women die from CRC than from any other malignant neoplasm, and it is the third most common cause of cancer death among men, after lung cancer and gastric cancer in Japan.
metastases depend on their resectability. 6 Similar guidelines are applicable for metachronous cancers. However, if the metastases are assessed as resectable, surgery is carried out, whereas systemic chemotherapy followed by evaluations for resectability every 2 months is recommended for unresectable liver metastases.
Even cases with multiple metastases can now be cured after resection as a result of recent advances in operative methods and chemotherapy. [7] [8] [9] Herein, we review and summarize the treatment options for CRLM. We also discuss recent advances in biomarker research for treatment decisions for liver metastasis.
| CATEGORIE S AND GUIDELINES FOR COLORECTAL LIVER METASTASIS
Japanese Society for Cancer of the Colon and Rectum has proposed a classification scheme for CRLM that combines findings of the presence or absence of liver metastases and number and size of metastases.
Analysis of registry cases using this classification scheme shows that the proportion of patients undergoing liver resection in categories H2
and H3 are smaller and that the prognoses are poorer than those in H1. 10 According to the JSCCR guidelines for the treatment of CRC, curative liver resection is recommended if the liver can be resected without leaving residual metastases, if the primary tumor is controlled or can be controlled, if there are no extrahepatic metastases or they can be controlled, and if remnant liver function can be preserved after resection.
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NCCN guidelines 12 indicate that the treatment options for liver or lung-limited synchronous metastases depend on their resectability.
Similar guidelines are applicable for metachronous cancers. The European Society for Medical Oncology guidelines 13 propose that treatment selection should be guided by the treatment intensity deemed necessary in advanced or recurrent CRC. In cases of wild-type liveronly disease, two-drug combination chemotherapy plus bevacizumab (Bmab) or cetuximab (Cmab) is recommended. Moreover, if the metastases are found to be resectable, resection is advised.
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| ABLATION THERAPY FOR CRLM
Although surgical resection is considered the gold standard for treatment of CRLM, only 10% to 20% of patients with liver metastases are deemed resectable. Metastasis is sometimes contraindicated for surgery because of anatomical reasons. Moreover, patients sometimes have comorbidities or liver dysfunction. In these cases, the patient is ineligible for major surgery. Instead, radiofrequency ablation (RFA) is often applied; however, the role of RFA in the management of CRLM is yet to be elucidated. The CLOCC trial randomized 119 patients with unresectable CRLM between RFA with FOLFOX (AEbevacizumab) vs FOLFOX (AEbevacizumab) alone. 27 The authors reported the superiority of RFA with FOLFOX (HR = 0.58, 95% CI:
0.38-0.88, P = .01). Other recent observational studies also showed the superiority of RFA combined with chemotherapy or surgery in terms of prognosis. [27] [28] [29] However, some studies have reported the risk of dissemination or incomplete ablation of RFA; therefore, the role of RFA for CRLM is controversial. In general, RFA should be considered in patients who are ineligible for resection as a result of anatomically unresectable lesions, functional insufficiency of hepatic reserve, medical comorbidities, and extrahepatic metastases.
| FOLFOX OR FOLFIRI FOR CRLM
According to previous clinical studies, the resection rate for liver metastasis is higher than that in other sites ( Steatohepatitis as a result of irinotecan-based chemotherapy possibly increasing the 90-day mortality rate (14.7%) is a cause for concern. 32 In combination with chemotherapy, the antiangiogenic drug bevacizumab protects against pathological changes of the liver parenchyma caused by chemotherapy, and its pathological benefits suggest that it could potentially improve prognosis.
In a retrospective study of sinusoidal dilatation in 105 patients who underwent liver resection after fluorouracil (5-FU)/oxaliplatin therapy with or without concomitant bevacizumab, Ribero et al 33 showed that the incidence of Rubbia-Brandt Grade 2-3 sinusoidal dilatation was 27.9% in patients treated without bevacizumab versus 8.1% in patients treated with bevacizumab (P = .006). Recently, in addition to inhibiting the development of oxaliplatin-induced sinusoidal dilatation, bevacizumab has also been reported to potentially inhibit splenomegaly and thrombocytopenia by inhibiting portal hypertension. 34 6 | NEOADJUVANT CHEMOTHERAPY FOR
RESE CTABLE CRLM
Usefulness of neoadjuvant chemotherapy (perioperative chemotherapy) for patients with CRC with up to four liver metastases was verified in the EORTC 40983 study. 35 In total, 364 patients were randomly assigned to treatment with either six cycles of pre-and postoperative FOLFOX4 (n = 182) or resection only (n = 182). In the intention-to-treat (ITT) analysis, the 3-year progression-free survival In the clinical studies that target unresectable CRC, the resection rate of liver metastasis is 4% to 15% [38] [39] [40] 44, 45 (Table 1) . However, in these trials, the patient with liver metastasis was not an allocation factor; thus, exact evaluation of the effect of chemotherapy for liver metastasis is difficult.
In clinical studies that targeted liver-only metastasis (Table 2) , the anti-epidermal growth factor receptor (EGFR) antibody cetuximab excellently improved the response rate and yield of curative liver resection, for which it has attracted attention. However, the definitions of unresectable liver metastasis in each clinical study for liver-only metastases from CRC varied among these studies (Table 3) .
Folprecht et al 46 reported the results of a randomized phase II study of FOLFOX/FOLFIRI plus cetuximab in patients with liver-only metastases from CRC. Among the 106 patients evaluated, the response and R0 resection rates were 68% and 38%, respectively, in the 53 patients receiving FOLFOX plus cetuximab, whereas they were 70% and 33%, respectively, in the 67 patients with KRAS wild-type status.
Addition of irinotecan in the 5-fluorouracil/folinic acid, oxaliplatin, irinotecan (FOLFOXIRI) regimen is effective for tumor shrinkage in CRLM. 47 The OLIVIA trial assessed the efficacy of bevacizumab plus modified FOLFOX-6 or FOLFOXIRI for patients with initially unresectable CRLM. Overall tumor response rate of the FOLFOXIRI arm was 81% (95% CI: 65%-91%), and the overall resection rate was 61% (95% CI: 45%-76%). 47 FOLFOXIRI + BV is also effective for patients with BRAF mutation, and this regimen can be selected for conversion therapy.
Regarding anti-EGFR antibody, panitumumab is effective for increasing the overall response rate (ORR) and resection rate. 48, 49 However, when determining the optimal multidisciplinary treatment strategy for KRAS wild-type liver-limited, initially unresectable CRC, no unequivocal evidence shows that molecular targeted therapy in combination with chemotherapy is better with either anti-VEGF antibody or anti-EGFR antibody despite the presence of data suggesting that "liver resection rate," "improvement of response rate," and "pathological improvement" improve prognosis. Recently, it was reported that anti-EGFR antibodies do not have survival benefit for RAS wild-type right-side colon cancer. 50, 51 However, the shrinkage of tumor is adequate even in right-side colon cancer. 52, 53 Therefore, anti-EGFR antibodies should be used cautiously for right-side RAS wild-type CRLM.
Previously, we conducted two independent phase II trials that targeted patients with CRLM, namely, KSCC0802 and KSCC1002. 54, 55 In the KSCC0802 multicenter trial, 40 patients with unresectable CRLM were included and received mFOLFOX6 + Bmab. Meanwhile, 33 patients with KRAS wild-type with unresectable CRLM were included from a trial of SOX (S-1 and oxaliplatin) plus Cmab in the KSCC1002 trial. In the KSCC0802 trial (mFOLFOX6 plus bevacizumab), the ORR was 42.5%, and R0 resection was achieved in 25% of the enrolled patients after chemotherapy. In the KSCC1002 trial (SOX plus cetuximab), the ORR was 63.6%, and R0 resection was achieved in 39.4% of the enrolled patients after chemotherapy. High tumor shrinkage mediated by SOX plus cetuximab led to high resectability for CRLM. Therefore, in the ATOM study, we planned a randomized phase II clinical study to conduct an exploratory comparison of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab in KRAS wild-type, difficult-toresect, liver-only metastases from CRC. We also investigated the differences in pathological response and morphological response between Bmab and Cmab. The results will be published in 2018.
| ADJUVANT CHEMOTHER APY AFTE R RESE CTION OF CRLM
In an investigation of the role of adjuvant chemotherapy following liver resection, the FFCD ACHBTH AURC 9002 study compared two treatments after curative liver resection: 5-FU/leucovorin (LV) for 6 months (n = 86) versus surgery alone (n = 85). 56 The 5 
| BIOMARKE RS FOR CRLM
Impact of tumor biology on prognosis in patients with CRLM has been the topic of intense research. Some systematic literature reviews show that KRAS and BRAF V600E mutations are negatively associated with OS and RFS in patients who undergo complete liver resection for CRLM. [60] [61] [62] [63] In particular, BRAF V600E mutations that present in 8%-10% of patients are consistently associated with poor prognosis and result in possible patient ineligibility for resection of CRLM. 64, 65 Recently, a small single-center cohort study showed that 21 of 52 patients with BRAF V600E mutant who underwent metastasectomy had longer OS (29.1 months vs 22.7 months) and PFS (13.6 months vs 6.2 months) compared with the non-metastasectomy cohort. The authors concluded that multimodality therapy incorporating metastasectomy for BRAF V600E metastatic CRC (mCRC) should be considered and might be associated with improved OS in selected patients. 66 Meanwhile, BRAF V600E can be a biomarker for selecting the appropriate chemotherapy regimen. Currently, FOLFOXIRI + BV might be the only effective regimen for multimodality treatment of the patient with BRAF V600E mutation; 67 therefore, BRAF mutation analysis should be done before treatment of CRLM.
Microsatellite instability (MSI) status or mismatch repair deficiency (MMR-D) has been the biomarker for adjuvant 5-FU monotherapy and immune checkpoint inhibitor. Hematogenous and lymphogenous metastasis-dominant CRC with high-frequency MSI (MSI-H) are reported to have poor prognosis. 68 However, the validity as the prognostic factor of MMR is yet to be confirmed, and it should thus be used cautiously. Primary location of the tumor is also a factor in treatment decision. Recent studies reported that rightsided primary tumors might be more likely to recur. 69, 70 In particular, palliative resection might not be done because these patients showed no benefit from resection. 69 Tumor biology should be further studied for precise treatment of CRLM. 
